- Cue Health Inc HLTH reported Q3 sales of $223.7 million, compared to +63% sequentially.
- Public Sector revenue was $129.5 million, compared to $105.0 in Q2 FY21, driven by additional deliveries to DOD / HHS under the existing agreement.
- Private Sector revenue was $94.2 million, compared to $32.4 million for the prior quarter, led by significant additions to the enterprise and provider customer base.
- Disposable test cartridge revenue was $179.0 million, +74% Q/Q.
- Product gross margin improved to 60.2% from 59.9% in Q2 FY21 due to increased production partially offset by higher labor and material costs.
- Net income was $19.3 million, a turnaround from a loss of $(8.5) million a year ago.
- Cash and cash equivalents were $446.6 million.
- Guidance: Cue Health expects FY21 revenues of $580.0 million - $590.0 million, higher than the consensus of 541.29 million.
- Price Action: HLTH shares closed at $11.12 on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in